Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR6508 in Hemodialysis Subjects With Secondary Hyperparathyroidism
NCT05663411Phase 2Unknown
- Sponsor
- Hengrui Therapeutics
- Start
- Feb 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SHR6508 in secondary hyperparathyroidism (SHPT) (3 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Change From Baseline in serum iPTH at Week 16. Status: unknown.
02
Drugs
SHR6508
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT05663411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663411.